Current Psychopharmacology
Title:Meet Our Associate Editorial Board Member
Volume: 9
Author(s): Dhanasekaran Sivaraman
Affiliation:
Export Options
About this article
Cite this article as:
Sivaraman Dhanasekaran , Meet Our Associate Editorial Board Member, Current Psychopharmacology 2020; 9 (1) . https://dx.doi.org/10.2174/221155600901200313154411
DOI https://dx.doi.org/10.2174/221155600901200313154411 |
Print ISSN 2211-5560 |
Publisher Name Bentham Science Publisher |
Online ISSN 2211-5579 |
Call for Papers in Thematic Issues
Breakthroughs in drug design, development and delivery system for the management of neuro-psychiatric disorders
Neuropsychiatric diseases are one of the main causes of disability, affecting millions of people. Various drugs are used for its treatment, although no effective therapy has been found yet. The blood brain barrier (BBB) significantly complicates drugs delivery to the target cells in the brain tissues. This proposal describes the ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Advances in Clinical Study of Curcumin
Current Pharmaceutical Design A Role of GABA Analogues in the Treatment of Neurological Diseases
Current Medicinal Chemistry Potential of Antibiotics for the Treatment and Management of Parkinson's Disease: An Overview
Current Drug Research Reviews Advances in Mucomodulator Therapy for Treatment of Excess Airway Mucus in Patients with Asthma, Chronic Obstructive Pulmonary Disease and Cystic Fibrosis
Recent Patents on Materials Science Rhinosinusitis in the Pediatric Patient with Cystic Fibrosis
Current Pediatric Reviews Non-viral Gene Delivery and Therapeutics Targeting to Brain
Current Nanoscience Prime Time for G-Protein-Coupled Receptor Heteromers as Therapeutic Targets for CNS disorders: The Dopamine D1-D3 Receptor Heteromer
CNS & Neurological Disorders - Drug Targets A Comparison Between Quetiapine and Aripiprazole for Treatment of Schizophrenia: A Double Blind Contrast
Current Psychopharmacology Borna Disease Virus (BDV): Neuropharmacological Effects of a CNS Viral Infection
Current Neuropharmacology Tau, Amyloid Beta and Deep Brain Stimulation: Aiming to Restore Cognitive Deficit in Alzheimer's Disease
Current Alzheimer Research Pharmacological Applications of Antioxidants: Lights and Shadows
Current Drug Targets Editorial [Hot topic: Parkinsons Disease (Guest Editor: Jurgen Dinges)]
Current Topics in Medicinal Chemistry Effect of Brain Derived Neurotrophic Factor (BDNF) Gene Variants on Therapeutic Response and the Risk for Schizophrenia
Current Pharmacogenomics Treating Rapid Cycling Bipolar Disorder with Novel Medications
Current Psychiatry Reviews Role of Vitamin E in Cellular Antioxidant Defense
Current Chemical Biology Pharmacogenetic and Pharmacogenomic Research in Psychiatry: Current Advances and Clinical Applications
Current Pharmacogenomics Mutations in PRKN and SNCA Genes Important for the Progress of Parkinson’s Disease
Current Genomics Advancement of Traditional Chinese Medicine in Regulation of Intestinal Flora: Mechanism-based Role in Disease Management
Recent Patents on Anti-Cancer Drug Discovery Editorial [ Hot Topic: Drugs Targets in Parkinson's Disease:Where Are We and Where should We Go? (Guest Editor: Mark R. Cookson)]
CNS & Neurological Disorders - Drug Targets Current Status of Antipsychotic Treatment
Current Drug Targets - CNS & Neurological Disorders